1 unknown. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Unknown 1 |
Follow Relapsed Adult AML: new trials by email Literature Review of Relapsed Adult AML trials Research Report on Relapsed Adult AML
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine,Cytarabine, G-CSF for Refractory or Relapsed AML Visilizumab - Immunotherapy, Refractory Leukemia | Phase 3 | Unknown | The First Affiliated Hospital of Soochow University | 30 | 2021-05-01 | 2021-12-03 |
Leukemia (1) · Leukemia, Myeloid, Acute (1) · Recurrence (1)
Disease Attributes (1) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Leukemia, Myeloid (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
Azacitidine (1) · Cytarabine (1) · Homoharringtonine (1) · visilizumab (1)
The First Affiliated Hospital of Soochow University (1)
China (1)
Han Yue, Ph.D (1)